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VALUE-BASED HEALTH CARE PAYMENT 
When it comes to improving the way health care providers 
are paid, value and care coordination are being rewarded – 
rather than volume and care duplication [1]. The U.S. 
Department of Health and Human Services is testing and 
expanding new health care payment models with the goals of 
improving health care quality and reducing its cost [1]. The 
‘Payment Taxonomy Framework’ [1] describes progression 
across four categories of payment: 
 
Category 1: fee-for-service with no link of 
payment to quality 
Category 2: fee-for-service with a link of 
payment to quality 
Category 3: alternative payment models built on 
fee-for-service architecture 
Category 4: population-based  
payment 
 
Value-based purchasing includes payments made in 
Categories 2 through 4. Moving from Category 1 to Category 
4 involves two shifts: (1) increasing accountability for both 
quality and total cost of care and (2) a greater focus on 
population health management as opposed to payment for 
specific products and services [1-3].  
 
Health care organizations have been making the shift toward 
increased collaboration, outcome-based payment, and new 
benefit design. This is changing the way entities pay for 
health care and how health care is delivered [4]. Value-based 
contracting models represent an evolution in clinical and 
payment methodologies aimed at creating quality and cost 
outcomes, fostering greater accountability, and taking 
advantage of innovations in medical technology [3,4]. These 
contract models align incentives across providers, members, 
employers, and payers to improve clinical outcomes and the 
patient experience along with improving cost efficiency [3-5].  
 
Many health care markets already have physician and 
hospital performance-based contracts, or capitation 
arrangements.  In response to health care reforms at national 
and state levels, there also has been growth in accountable 
care organizations (ACOs), with payment and care delivery 
models that tie provider reimbursements to quality metrics 
and reductions in the total cost of care for an assigned 
population of patients. 
 
 
VALUE-BASED PHARMACEUTICAL PAYMENT 
The same pressure that is being applied to health-systems, 
providers, and patient care programs is likely for value-based 
assessment of pharmaceuticals.  Questions about (1) 
improving the patient experience of care, (2) improving the 
health of populations, and (3) reducing the per capita cost of 
health care (the Triple Aim) are relevant in the 
pharmaceutical domain [6].  
 
In order to meet value-based care goals from the use of 
pharmaceuticals, patients themselves are responsible for 
engaging in behaviors, participating in self-monitoring, and 
providing information. In addition, patient variability needs to 
be taken into account which includes such things as genes, 
environment, personality, and lifestyle for each person – 
often referred to as “precision medicine” [7]. While 
significant advances in precision medicine have been made 
for treating select cancers, the practice is not currently in use 
for most diseases, especially pharmaceutical treatment of 
chronic diseases for which self-management and monitoring 
by patients themselves are needed.  
 
Typically, the health care system views pharmaceutical 
product use in terms of clinical problem-solving (prescribing, 
monitoring, reconciling) and in terms of medication regimen 
adherence and persistence (following directions). However, 
the use of pharmaceutical products by patients is affected by 
their medication beliefs, personal abilities and motivations, 
information processing, decision-making, relationships, 
finances, and the effects of life experiences [8-9]. Patients 
vary widely in their make-up, their preferences, and their 
needs. As people use pharmaceutical products, there is a high 
likelihood that they will involve a personal contact, either lay 
or professional, to help them [10-12]. Patients have different 
abilities, motivations, and needs when it comes to 
pharmaceutical use. The challenge, then, is to meet the needs 
of each individual within the broader context of populations 
and to reflect this in value-based assessments. When making 
drug approval and drug use decisions for populations of 
patients, these individual differences must be considered in 
targeting pharmaceutical interventions and management to 
patient populations.  
 
VALUE-BASED FORMULARY DECISION-MAKING 
In the United States, the Food and Drug Administration (FDA) 
makes decisions about the safety and effectiveness of 
pharmaceutical products through the use of clinical trials 
which are tightly controlled studies. Clinical trials, also known 
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as clinical studies, test potential treatments in human 
volunteers to see whether they should be approved for wider 
use in the general population. With tight controls employed 
in these studies, little attention is given to variation in patient 
characteristics or to replication under varied conditions. 
 
After a drug is approved for use by the FDA, formulary 
committees make decisions about the comparative 
effectiveness and value of pharmaceuticals on behalf of 
health plans that, in turn, represent populations of patients. 
Typically, claims for justifying the acceptance and placement 
of pharmaceutical products on health system formularies, are 
presented in “potential-value” terms that are either 
unevaluable or only evaluable in a timeframe or under 
conditions that are of no practical benefit for making 
utilization-based value judgments.  
 
To address the gap between current practice and the value-
based payment approaches that have emerged, Dr. Langley 
and colleagues have published a series of commentaries that 
lay a foundation for taking next steps in validating 
pharmaceutical product claims [13-17]. The principles are 
rooted in (1) addressing value-based care, (2) making 
evaluations practical, (3) using technical standards, (4) 
developing validation protocols, (5) using explicit formats, (6) 
conducting formal review, and (7) collaborating on access to 
data [13-17]. They have proposed that evaluating claims for 
pharmaceutical products and devices should be seen as a 
necessary part of any program of continuous quality 
improvement in health care delivery.  The absence of 
feedback to formulary committees, health care providers, 
and other decision-makers regarding pharmaceutical product 
performance is a major and contributing gap in the ability to 
deliver effective, affordable and high quality healthcare.  
 
To build upon that series of commentaries, Dr. Paul Langley is 
guiding work at the University of Minnesota, Graduate 
Program in Social and Administrative Pharmacy to generate 
discovery, discussion, and debate about the transformation 
that is needed in Guidelines for Formulary Evaluations so 
that value-based assessment of pharmaceutical products and 
services can be achieved and meet the greater expectations 
of “better care, smarter spending, and healthier people [18].” 
INNOVATIONS in pharmacy is pleased to serve as a 
communication venue for this effort. In addition to Dr. 
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